HALOZYME THERAPEUTICS, INC. financials

  1. Home
  2. Financials
  3. HALO
HALO CIK 0001159036

Source: EDGAR filings · Built 2026-06-02T03:11:16Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 644.59M 468.37M 373.28M 235.30M 297.98M 52.95M
EBITDA 480.39M 561.74M 348.66M 274.02M 278.90M 147.54M
Working Capital 648.12M 946.24M 633.93M 608.22M 809.14M 133.38M
Net Debt 2.04B 1.42B 1.41B 1.31B 760.77M 254.39M
Gross Margin 83.62% 84.30% 76.80% 78.90% 81.64% 2.31%
Operating Margin 33.58% 54.32% 40.71% 40.53% 62.24% 53.91%
Net Margin 22.69% 43.74% 33.96% 30.62% 90.84% 48.24%
Return on Equity (ROE) 649.18% 122.06% 336.00% 119.04% 204.47% 85.46%
Return on Assets (ROA) 12.55% 21.52% 16.25% 10.98% 36.46% 22.26%
Current Ratio 4.66× 7.80× 6.64× 5.65× 7.91× 1.32×
Debt-to-Equity 44.60× 4.22× 18.27× 9.07× 4.47× 2.66×
Effective Tax Rate 32.13% 20.29% 19.16% 18.80% -62.04% 0.17%
Cash Conversion Ratio 2.06× 1.08× 1.38× 1.19× 0.74× 0.43×
Accruals Ratio -0.13× -0.02× -0.06× -0.02× 0.09× 0.13×
SBC % of Revenue 3.69% 4.27% 4.42% 3.70% 4.70% 6.43%
CapEx Coverage 93.48× 44.79× 25.41× 49.92× 205.52× 22.15×
Free Cash Flow Per Share $5.20 $3.62 $2.78 $1.67 $2.03 $0.37

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 26.29× 13.94× 17.60× 39.51× 14.68× 46.93×
P/FCF 12.94× 13.21× 13.29× 34.00× 19.81× 114.11×
FCF Yield 7.73% 7.57% 7.53% 2.94% 5.05% 0.88%
EV / EBITDA 20.75× 13.01× 17.49× 32.83× 22.55× 40.81×
P/S 5.68× 5.80× 5.65× 11.65× 12.47× 21.55×
P/B 162.39× 16.18× 55.91× 45.29× 28.07× 38.18×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.40B 1.02B 829.25M 660.12M 443.31M 267.59M
Revenues — — — — — 121.70M
Cost of Goods and Services Sold 228.77M 159.42M 192.36M 139.30M 81.41M 43.37M
Gross Profit — — — — — 6.18M
Research and Development Expense — 79.05M 76.36M 66.61M 35.67M 34.24M
Selling, General and Administrative Expense 207.09M 154.34M 149.18M 143.53M 50.32M 45.74M
Operating Expenses — — — — — 44.08M
Operating Income (Loss) 469.01M 551.48M 337.57M 267.53M 275.90M 144.25M
Income Tax Expense (Benefit) 149.99M 113.04M 66.73M 46.79M -154.19M 217.00K
Net Income (Loss) Attributable to Parent 316.89M 444.09M 281.59M 202.13M 402.71M 129.09M
Earnings Per Share, Basic $2.64 $3.50 $2.13 $1.48 $2.86 $0.95
Weighted Average Number of Shares Outstanding, Basic 119.84M 126.83M 131.93M 136.84M 140.65M 136.21M
Earnings Per Share, Diluted $2.56 $3.43 $2.10 $1.44 $2.74 $0.91
Weighted Average Number of Shares Outstanding, Diluted 123.90M 129.42M 134.20M 140.61M 146.80M 141.46M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 133.82M 115.85M 118.37M 234.19M 118.72M 147.70M
Assets, Current 825.21M 1.09B 746.42M 739.01M 926.29M 554.76M
Assets 2.53B 2.06B 1.73B 1.84B 1.10B 579.92M
Long-term Debt 2.14B 1.51B 1.50B 1.51B 787.25M 0
Liabilities, Current 177.09M 139.10M 112.49M 130.79M 117.15M 421.38M
Long-term Debt, Excluding Current Maturities 2.14B 1.51B 1.50B 1.49B 787.25M 0
Liabilities 2.48B 1.70B 1.65B 1.67B — —
Stockholders' Equity Attributable to Parent 48.81M 363.82M 83.81M 169.80M 196.95M 151.05M
Common Stock, Shares, Outstanding 117.78M 123.14M 126.77M 135.15M 137.50M 135.03M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 651.56M 479.06M 388.57M 240.11M 299.44M 55.45M
Payments to Acquire Property, Plant, and Equipment 6.97M 10.70M 15.29M 4.81M 1.46M 2.50M
Net Cash Provided by (Used in) Investing Activities -545.81M -262.72M -96.91M -487.00M -406.29M 78.35M
Payments for Repurchase of Common Stock 342.37M 250.00M 402.38M 200.00M 350.06M 150.12M
Net Cash Provided by (Used in) Financing Activities -85.17M -218.86M -407.99M 362.37M 77.86M -106.28M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (HALO CIK 0001159036), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ANAB

ANAPTYSBIO, INC.

GLSI

GREENWICH LIFESCIENCES, INC.

PRLB

Proto Labs, Inc.